Media Room
Fourth Quarter & Full Year 2025 Results
Fourth quarter and full year 2025 results will be reviewed by management during a live audio webcast with the financial community on January 29, 2026. The presentation will be followed by a Q&A session.
Press releases
January 12, 2026
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
January 5, 2026
Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
Half year 2025 financial report XBRL package
Half Year 2025 Financial Report
Sustainability Statement 2024 (ESG Report)
Registration Document 2024 (in French)